Seth S Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5756260/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radar-based monitoring system for medication tampering using data augmentation and multivariate time series classification. Smart Health, 2022, 23, 100245.	2.0	3
2	Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation, 2022, 145, CIR00000000000001052.	1.6	2,561
3	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)â€Free Lowâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2022, 11, e023136.	1.6	8
4	Application of the very high risk criterion and evaluation of cholesterol guideline adherence in acute myocardial infarction patients at an urban academic medical center. American Heart Journal Plus, 2022, 13, 100082.	0.3	0
5	What is the Optimal Low-Density Lipoprotein Cholesterol?. Medical Clinics of North America, 2022, 106, 285-298.	1.1	2
6	Quantifying the contribution of lipoprotein(a) to all apoB containing particles. Journal of Clinical Lipidology, 2022, 16, 220-226.	0.6	3
7	Discordance Between Standard Equations for Determination of LDLÂCholesterol in Patients WithÂAtherosclerosis. Journal of the American College of Cardiology, 2022, 79, 530-541.	1.2	16
8	Abstract P093: Subclinical Thyroid Dysfunction And Fracture Risk In The Atherosclerosis Risk In Communities Study (ARIC). Circulation, 2022, 145, .	1.6	0
9	Contemporary Management of Dyslipidemia. Drugs, 2022, 82, 559-576.	4.9	14
10	Abstract P234: Electronic Medical Record Use Among Adults With Self-reported Hypertension: Analysis Of The 2020 Health Information National Trends Survey. Circulation, 2022, 145, .	1.6	0
11	Contextualizing National Policies Regulating Access to Lowâ€Dose Aspirin in America and Europe Using the Full Report of a Transatlantic Patient Survey of Aspirin in Preventive Cardiology. Journal of the American Heart Association, 2022, 11, e023995.	1.6	2
12	Association of Online Search Trends With Vaccination in the United States: June 2020 Through May 2021. Frontiers in Immunology, 2022, 13, 884211.	2.2	4
13	Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis. Current Atherosclerosis Reports, 2022, 24, 571-581.	2.0	8
14	Cardio-Obstetrics: the Next Frontier in Cardiovascular Disease Prevention. Current Atherosclerosis Reports, 2022, 24, 493-507.	2.0	7
15	Starting a Research Career in Cardiology: Advice for Fellows in Training and Early-Career Cardiologists. Methodist DeBakey Cardiovascular Journal, 2022, 18, 49-58.	0.5	0
16	Building a hybrid virtual cardiac rehabilitation program to promote health equity: Lessons learned. Cardiovascular Digital Health Journal, 2022, 3, 158-160.	0.5	6
17	Interprofessional education and collaboration among healthcare students and professionals: a systematic review and call for action. Journal of Interprofessional Care, 2021, 35, 1-10.	0.8	67
18	Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm. Journal of Clinical Lipidology, 2021, 15, 104-115.e9.	0.6	6

#	Article	IF	CITATIONS
19	Digital Health. , 2021, , 111-131.		0
20	Digital Health Interventions for Cardiac Rehabilitation: Systematic Literature Review. Journal of Medical Internet Research, 2021, 23, e18773.	2.1	77
21	Heart Rate Measurements in Patients with Obstructive Sleep Apnea and Atrial Fibrillation: Prospective Pilot Study Assessing Apple Watch's Agreement With Telemetry Data. JMIR Cardio, 2021, 5, e18050.	0.7	4
22	Heart Disease and Stroke Statistics—2021 Update. Circulation, 2021, 143, e254-e743.	1.6	3,444
23	User Engagement With Smartphone Apps and Cardiovascular Disease Risk Factor Outcomes: Systematic Review. JMIR Cardio, 2021, 5, e18834.	0.7	38
24	Smart wearable devices in cardiovascular care: where we are and how to move forward. Nature Reviews Cardiology, 2021, 18, 581-599.	6.1	319
25	Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1229-1238.	1.1	19
26	Opportunities to improve cardiovascular health in the new American workplace. American Journal of Preventive Cardiology, 2021, 5, 100136.	1.3	1
27	Heart rate trajectories in patients recovering from acute myocardial infarction: A longitudinal analysis of Apple Watch heart rate recordings. Cardiovascular Digital Health Journal, 2021, 2, 270-281.	0.5	4
28	Sociodemographic Characteristics Predicting Digital Health Intervention Use After Acute Myocardial Infarction. Journal of Cardiovascular Translational Research, 2021, 14, 951-961.	1.1	13
29	The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review. Expert Review of Precision Medicine and Drug Development, 2021, 6, 247-258.	0.4	11
30	Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. European Journal of Internal Medicine, 2021, 87, 3-12.	1.0	10
31	The Johns Hopkins Ciccarone Center's expanded †ABC's approach to highlight 2020 updates in cardiovascular disease prevention. American Journal of Preventive Cardiology, 2021, 6, 100181.	1.3	0
32	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. European Heart Journal, 2021, 42, 4324-4332.	1.0	135
33	Mobile health in preventive cardiology: current status and future perspective. Current Opinion in Cardiology, 2021, 36, 580-588.	0.8	12
34	Digital Health Intervention in Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007741.	0.9	33
35	Understanding myocardial infarction trends during the early COVID â€19 pandemic: an infodemiology study. Internal Medicine Journal, 2021, 51, 1328-1331.	0.5	2
36	Health Information Technology Use Among Persons With Self-reported Atherosclerotic Cardiovascular Disease: Analysis of the 2011-2018 National Health Interview Survey. Journal of Medical Internet Research, 2021, 23, e23765.	2.1	8

#	Article	IF	CITATIONS
37	Daily Step Counts Are Associated with Hospitalization Risk in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1338-1340.	2.5	8
38	Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines. American Journal of Preventive Cardiology, 2021, 7, 100203.	1.3	2
39	A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension. Chest, 2021, 160, 1042-1052.	0.4	16
40	A simplified approach to identification of risk status in patients with atherosclerotic cardiovascular disease. American Journal of Preventive Cardiology, 2021, 7, 100187.	1.3	6
41	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. Journal of Clinical Lipidology, 2021, 15, 629-648.	0.6	69
42	A Transatlantic Comparison of Patient-Reported Access to and Use of Aspirin in Contemporary Preventive Cardiology. Journal of the American College of Cardiology, 2021, 78, 1193-1195.	1.2	7
43	Cost-effectiveness of a Digital Health Intervention for Acute Myocardial Infarction Recovery. Medical Care, 2021, 59, 1023-1030.	1.1	13
44	Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels. JAMA Network Open, 2021, 4, e2128817.	2.8	40
45	Abstract 10918: Use of Mobile Health Technology in the Assessment of Statin-Associated Muscle Symptoms (SAMS). Circulation, 2021, 144, .	1.6	0
46	Abstract 11258: Engaging Diverse Patients, Caregivers, and Clinicians as Partners to Identify Disease Management Related Challenges in Atrial Fibrillation: <i>A Qualitative Study Utilizing Human-Centered Design Methodology</i> . Circulation, 2021, 144, .	1.6	1
47	Comprehensive Digital Health Intervention to Improve Delivery of Cardiac Rehabilitation. , 2021, , .		1
48	Clinicians for CARE: A Systematic Review and Metaâ€Analysis of Interventions to Support Caregivers of Patients With Heart Disease. Journal of the American Heart Association, 2021, 10, e019706.	1.6	8
49	Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors. Npj Digital Medicine, 2021, 4, 168.	5.7	13
50	An Individualized, Data-Driven Digital Approach for Precision Behavior Change. American Journal of Lifestyle Medicine, 2020, 14, 289-293.	0.8	24
51	Clinical significance of zero coronary artery calcium in individuals with LDL cholesterol ≥190â€ ⁻ mg/dL: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2020, 292, 224-229.	0.4	38
52	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology, 2020, 27, 1597-1605.	0.8	41
53	Prevalence of familial chylomicronemia syndrome in a quaternary care center. European Journal of Preventive Cardiology, 2020, 27, 2276-2278.	0.8	8
54	How useful is the smartwatch ECG?. Trends in Cardiovascular Medicine, 2020, 30, 442-448.	2.3	142

#	Article	IF	CITATIONS
55	Incorporating Health Behavior Theory into mHealth: an Examination of Weight Loss, Dietary, and Physical Activity Interventions. Journal of Technology in Behavioral Science, 2020, 5, 51-60.	1.3	10
56	Short Communication: Comparison of Calculated Low-Density Lipoprotein Cholesterol (LDL-C) Values in HIV-Infected and HIV-Uninfected Men Using the Traditional Friedewald and the Novel Martin–Hopkins LDL-C Equations. AIDS Research and Human Retroviruses, 2020, 36, 176-179.	0.5	5
57	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 1091-1100.	0.8	61
58	Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Current Atherosclerosis Reports, 2020, 22, 72.	2.0	14
59	Digital Cardiology: Opportunities for Disease Prevention. Current Cardiovascular Risk Reports, 2020, 14, 1.	0.8	7
60	Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 2020, 4, 100130.	1.3	142
61	Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events. JAMA - Journal of the American Medical Association, 2020, 324, 2262.	3.8	32
62	Is cuffless blood pressure measurement already here?. Journal of Hypertension, 2020, 38, 774-775.	0.3	10
63	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Archives of Medical Science, 2020, 16, 1279-1287.	0.4	11
64	Vascular Disease Patient Information Page: Understanding cholesterol. Vascular Medicine, 2020, 25, 507-510.	0.8	1
65	Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). Archives of Medical Science, 2020, 16, 993-1003.	0.4	20
66	Accuracy of New Equation to Calculate Low-Density Lipoprotein Cholesterol. JAMA Cardiology, 2020, 6, 121-122.	3.0	4
67	Early blood pressure assessment after acute myocardial infarction: Insights using digital health technology. American Journal of Preventive Cardiology, 2020, 3, 100089.	1.3	3
68	Factoring in ANGPTL3 When LDL Is Refractory. New England Journal of Medicine, 2020, 383, 2385-2386.	13.9	4
69	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. American Journal of Preventive Cardiology, 2020, 1, 100009.	1.3	90
70	Cuff-less, Personal, Ambulatory Blood Pressure Devices and Disruption of Existing Blood Pressure Measurement Paradigms. American Journal of Hypertension, 2020, 33, 813-815.	1.0	1
71	Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease's â€~ABC's Approach. American Journal of Preventive Cardiology, 2020, 2, 100027.	1.3	6
72	Mobile health application platform â€ [~] Corrie' personalises and empowers the heart attack recovery patient experience in the hospital and at home for an underserved heart attack survivor. BMJ Case Reports, 2020, 13, e231801.	0.2	7

#	Article	IF	CITATIONS
73	Innovation without integration. Npj Digital Medicine, 2020, 3, 15.	5.7	6
74	Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation, 2020, 141, e139-e596.	1.6	5,545
75	Highâ€Sensitivity Câ€Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. Journal of the American Heart Association, 2020, 9, e013600.	1.6	43
76	More accurate LDL-C calculation: Externally validated, guideline endorsed. Clinica Chimica Acta, 2020, 506, 149-153.	0.5	34
77	Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 331-338.	0.6	4
78	Using Mobile Health Tools to Assess Physical Activity Guideline Adherence and Smoking Urges: Secondary Analysis of mActive-Smoke. JMIR Cardio, 2020, 4, e14963.	0.7	0
79	Abstract MP70: Conventional and Novel Lipid Measures and Subsequent Risk of Lower-extremity Peripheral Artery Disease: The Atherosclerosis Risk in Communities (aric) Study. Circulation, 2020, 141,	1.6	0
80	Abstract MP72: Using Non-HDL-C/Triglyceride Ratio To Screen For Direct LDL-C Testing: Improving LDL-C Estimates At A Cost. Circulation, 2020, 141, .	1.6	0
81	Abstract P197: Health Information Technology Use Among Patients With Diagnosed Atherosclerotic Cardiovascular Disease: Evidence From The 2010-2018 National Health Interview Survey. Circulation, 2020, 141, .	1.6	0
82	Abstract 14845: Remnant Cholesterol and Incident Atherosclerotic Cardiovascular Disease: A Pooled Cohort Primary Prevention Study. Circulation, 2020, 142, .	1.6	0
83	Abstract 15661: Discordant LDL-C Estimates and Incident Atherosclerotic Cardiovascular Disease: The Dallas Heart Study. Circulation, 2020, 142, .	1.6	0
84	Abstract 15079: Equitable Access to MHealth Through a Smartphone Loaner Program in Patients With Acute Myocardial Infarction. Circulation, 2020, 142, .	1.6	0
85	Abstract 14691: Heart Rate Trajectories and Clinical Correlates in Patients Recovering From Acute Myocardial Infarction: A Longitudinal Analysis of Apple Watch Heart Rate Recordings. Circulation, 2020, 142, .	1.6	0
86	Cardiovascular Risk Heterogeneity in Adults with Diabetes: Selective Use of Coronary Artery Calcium in Statin Use Decision-making. Journal of General Internal Medicine, 2019, 34, 2643-2647.	1.3	6
87	The role of a clinician amid the rise of mobile health technology. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 1385-1388.	2.2	11
88	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. Journal of Clinical Lipidology, 2019, 13, 634-644.	0.6	32
89	Novel Presentation of Homozygous Familial Hypercholesterolemia WithÂHomozygous Variants in BothÂLDLRÂand APOB Genes. JACC: Case Reports, 2019, 1, 346-349.	0.3	0
90	Achievement of Very Low Low-Density Lipoprotein Cholesterol Levels. Circulation, 2019, 140, 2063-2066.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. Journal of Clinical Lipidology, 2019, 13, 804-811.e2.	0.6	10
92	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis, 2019, 289, 85-93.	0.4	60
93	Prevalence and Risk Factors of Thyroid Dysfunction in Older Adults in the Community. Scientific Reports, 2019, 9, 13156.	1.6	34
94	Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation, 2019, 139, e56-e528.	1.6	6,192
95	Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription. Journal of the American Heart Association, 2019, 8, e010241.	1.6	23
96	Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Current Atherosclerosis Reports, 2019, 21, 31.	2.0	8
97	LDL-C Targets in Secondary Prevention: How Low Should We Go?. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	4
98	Connected Health Technology for Cardiovascular Disease Prevention and Management. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 29.	0.4	27
99	Corrie Health Digital Platform for Self-Management in Secondary Prevention After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005509.	0.9	39
100	JCL roundtable: Lipid treatment targets. Journal of Clinical Lipidology, 2019, 13, 223-230.	0.6	1
101	Digital health technology and mobile devices for the management of diabetes mellitus: state of the art. Diabetologia, 2019, 62, 877-887.	2.9	210
102	How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic Proceedings, 2019, 94, 660-669.	1.4	6
103	A randomized controlled trial of online symptom searching to inform patient generated differential diagnoses. Npj Digital Medicine, 2019, 2, 110.	5.7	10
104	Mobile Health Access and Use Among Individuals With or At Risk for Cardiovascular Disease: 2018 Health Information National Trends Survey (HINTS). Journal of the American Heart Association, 2019, 8, e014390.	1.6	28
105	Lipoprotein Sub-Fractions by Ion-Mobility Analysis and Its Association with Subclinical Coronary Atherosclerosis in High-Risk Individuals. Journal of Atherosclerosis and Thrombosis, 2019, 26, 50-63.	0.9	16
106	Abstract 26: The Corrie Myocardial infarction, COmbined-device, Recovery Enhancement (MiCORE) Study: 30-Day Readmission Rates and Cost-Effectiveness of a Novel Digital Health Intervention for Acute Myocardial Infarction Patients. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, .	0.9	2
107	Technical Guidance for Clinicians Interested in Partnering With Engineers in Mobile Health Development and Evaluation. JMIR MHealth and UHealth, 2019, 7, e14124.	1.8	6
108	Strategies for the Successful Implementation of a Novel iPhone Loaner System (iShare) in mHealth Interventions: Prospective Study. JMIR MHealth and UHealth, 2019, 7, e16391.	1.8	18

#	Article	IF	CITATIONS
109	Lipid analysis in an aging population. Aging, 2019, 11, 1073-1074.	1.4	0
110	Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?. Current Atherosclerosis Reports, 2018, 20, 14.	2.0	11
111	Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation, 2018, 138, 244-254.	1.6	34
112	Harnessing mHealth technologies to increase physical activity and prevent cardiovascular disease. Clinical Cardiology, 2018, 41, 985-991.	0.7	29
113	Relationship of Lipids and Lipid-Lowering Medications With Cognitive Function. American Journal of Epidemiology, 2018, 187, 767-776.	1.6	10
114	Statin Safety: What Every Health Care Provider Needs to Know. Current Cardiovascular Risk Reports, 2018, 12, 1.	0.8	1
115	Inflammation and Cardiovascular Disease Risk: A Case Study of HIV and Inflammatory Joint Disease. American Journal of Medicine, 2018, 131, 442.e1-442.e8.	0.6	4
116	Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy. Circulation, 2018, 137, 10-19.	1.6	92
117	Effect of Evolocumab on Lipoprotein Particles. American Journal of Cardiology, 2018, 121, 308-314.	0.7	29
118	Screening for Atherosclerotic Cardiovascular Disease in Asymptomatic Individuals. , 2018, , 459-478.		2
119	Uncommon presentation, rare complication and previously undescribed oncologic association of pheochromocytoma; the great masquerader. BMJ Case Reports, 2018, 2018, bcr-2017-223993.	0.2	1
120	Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. Current Cardiovascular Risk Reports, 2018, 12, 1.	0.8	2
121	The spectrum of type III hyperlipoproteinemia. Journal of Clinical Lipidology, 2018, 12, 1383-1389.	0.6	40
122	Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. Circulation, 2018, 138, 767-769.	1.6	2
123	Introducing the â€~Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statinâ€associated muscle symptoms, under blinded and open″abel conditions. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 1023-1033.	2.9	84
124	User experience of instant blood pressure: exploring reasons for the popularity of an inaccurate mobile health app. Npj Digital Medicine, 2018, 1, 31.	5.7	15
125	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. Journal of Lipid Research, 2018, 59, 1266-1275.	2.0	62
126	Online Health Searches and Their Perceived Effects on Patients and Patient-Clinician Relationships: ASystematic Review. American Journal of Medicine, 2018, 131, 1250.e1-1250.e10.	0.6	27

#	Article	IF	CITATIONS
127	Novel Therapeutic Targets for Managing Dyslipidemia. Trends in Pharmacological Sciences, 2018, 39, 733-747.	4.0	31
128	Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?. Atherosclerosis, 2018, 277, 172-174.	0.4	3
129	Trends in user ratings and reviews of a popular yet inaccurate blood pressure-measuring smartphone app. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1074-1079.	2.2	28
130	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. JAMA Cardiology, 2018, 3, 749.	3.0	105
131	Auralife Instant Blood Pressure App in Measuring Resting Heart Rate: Validation Study. JMIR Biomedical Engineering, 2018, 3, e11057.	0.7	1
132	Digital Health Innovation: A Toolkit to Navigate From Concept to Clinical Testing. JMIR Cardio, 2018, 2, e2.	0.7	22
133	mActive-Smoke: A Prospective Observational Study Using Mobile Health Tools to Assess the Association of Physical Activity With Smoking Urges. JMIR MHealth and UHealth, 2018, 6, e121.	1.8	5
134	Increasing Physical Activity Amongst Overweight and Obese Cancer Survivors Using an Alexa-Based Intelligent Agent for Patient Coaching: Protocol for the Physical Activity by Technology Help (PATH) Trial. JMIR Research Protocols, 2018, 7, e27.	0.5	30
135	Wearable Technology and Long-term Weight Loss. JAMA - Journal of the American Medical Association, 2017, 317, 318.	3.8	0
136	Addressing Knowledge Gaps in the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Review of Recent Coronary Artery Calcium Literature. Current Atherosclerosis Reports, 2017, 19, 7.	2.0	7
137	Trends in the Use of Moderate-Intensity to High-Intensity Statin and Nonstatin Lipid-Lowering Therapy: Turning Off the Faucet Is Much More Valuable Than Mopping Up the Floor. JAMA Cardiology, 2017, 2, 355.	3.0	4
138	Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. Aids, 2017, 31, 965-971.	1.0	4
139	JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1). Journal of Clinical Lipidology, 2017, 11, 587-595.	0.6	1
140	JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). Journal of Clinical Lipidology, 2017, 11, 846-854.	0.6	1
141	Thyroid Function, Cardiovascular Risk Factors, and Incident Atherosclerotic Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3306-3315.	1.8	50
142	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FHâ,,¢ patient registry. Atherosclerosis, 2017, 267, 19-26.	0.4	64
143	Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. Journal of Clinical Lipidology, 2017, 11, 1458-1470.e4.	0.6	14
	Chating Madising 2017 22 442 445	-	-

144 Statins. Vascular Medicine, 2017, 22, 442-445.

0.8 8

#	Article	IF	CITATIONS
145	Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy. Annals of Internal Medicine, 2017, 167, 256.	2.0	151
146	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. Journal of the American Heart Association, 2017, 6, .	1.6	39
147	Digital Health Technologies to Promote Lifestyle Change and Adherence. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 60.	0.4	45
148	Physical Activity, Vitamin D, and Incident Atherosclerotic Cardiovascular Disease in Whites and Blacks: The ARIC Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1227-1236.	1.8	24
149	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. BMC Medicine, 2017, 15, 83.	2.3	38
150	Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy. Circulation, 2017, 135, 153-165.	1.6	83
151	Associations of Coffee, Tea, and Caffeine Intake with Coronary Artery Calcification and Cardiovascular Events. American Journal of Medicine, 2017, 130, 188-197.e5.	0.6	39
152	Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk. Archives of Medical Science, 2017, 4, 732-737.	0.4	48
153	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol &It70Âmg/dL compared with a novel low-density lipoprotein estimation method. Journal of Clinical Lipidology, 2017, 11, 1065-1072.	0.6	37
154	Harnessing Connected Health to Improve Hospital Discharge and Patient Outcomes for Every Generation: Insights from Piloting the Corrie Platform in Post-MI Recovery. Iproceedings, 2017, 3, e27.	0.1	0
155	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
156	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World Journal of Cardiology, 2016, 8, 201.	0.5	47
157	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. American Journal of Cardiology, 2016, 118, 647-655.	0.7	21
158	Serum homocysteine is not independently associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-21) study. Atherosclerosis, 2016, 249, 59-64.	0.4	10
159	Validation of the Instant Blood Pressure Smartphone App. JAMA Internal Medicine, 2016, 176, 700.	2.6	139
160	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. Future Cardiology, 2016, 12, 139-148.	0.5	5
161	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Journal of the American Heart Association, 2016, 5, .	1.6	121
162	Shared Decision-Making and Patient Empowerment in Preventive Cardiology. Current Cardiology Reports, 2016, 18, 49.	1.3	89

#	Article	IF	CITATIONS
163	Critical Flaws in the Validation of the Instant Blood Pressure Smartphone App—A Letter from the App Developers—Reply. JAMA Internal Medicine, 2016, 176, 1410.	2.6	6
164	Reply. Journal of the American College of Cardiology, 2016, 68, 1710-1711.	1.2	0
165	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016, 253, 194-208.	0.4	142
166	The Case For and Against a CoronaryÂArteryÂCalcium Trial. JACC: Cardiovascular Imaging, 2016, 9, 994-1002.	2.3	25
167	Response to the Letter Regarding Article, "Bringing Back Targets to â€~IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?â€: Circulation, 2016, 133, e462.	1.6	0
168	Vitamin D deficiency is independently associated with greater prevalence of erectile dysfunction: The National Health and Nutrition Examination Survey (NHANES) 2001–2004. Atherosclerosis, 2016, 252, 61-67.	0.4	45
169	Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, The, 2016, 388, 2532-2561.	6.3	1,399
170	Role of Statins in Glucose Homeostasis and Insulin Resistance. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	1
171	What to say and how to say it. Current Opinion in Cardiology, 2016, 31, 537-544.	0.8	28
172	Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: AÂCritique. American Journal of Medicine, 2016, 129, 906-912.	0.6	6
173	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids in Health and Disease, 2016, 15, 28.	1.2	36
174	Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opinion on Pharmacotherapy, 2016, 17, 1497-1507.	0.9	43
175	The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 237-244.	1.8	142
176	Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia. Atherosclerosis, 2016, 246, 1-6.	0.4	8
177	The Wild Wild West: A Framework to Integrate mHealth Software Applications and Wearables to Support Physical Activity Assessment, Counseling and Interventions for Cardiovascular Disease Risk Reduction. Progress in Cardiovascular Diseases, 2016, 58, 584-594.	1.6	90
178	Approach to Statin Use in 2016: an Update. Current Atherosclerosis Reports, 2016, 18, 20.	2.0	26
179	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. Future Cardiology, 2016, 12, 149-157.	0.5	7
180	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacological Research, 2016, 103, 236-252.	3.1	60

#	Article	IF	CITATIONS
181	Fasting or Nonfasting Lipid Measurements. Journal of the American College of Cardiology, 2016, 67, 1227-1234.	1.2	63
182	Relationship Between Sedentary Behavior and Cardiovascular Risk. Current Cardiology Reports, 2016, 18, 6.	1.3	73
183	Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study. Journal of Clinical Lipidology, 2016, 10, 72-81.e1.	0.6	71
184	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. European Journal of Preventive Cardiology, 2016, 23, 41-49.	0.8	64
185	Newer Lipid Markers: Apolipoprotein B, LDL Particle Concentration, and Triglyceride-Rich Lipoproteins – When Are They Needed?. , 2016, , 145-158.		0
186	mActive: A Randomized Clinical Trial of an Automated mHealth Intervention for Physical Activity Promotion. Journal of the American Heart Association, 2015, 4, .	1.6	220
187	Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry. Clinical Cardiology, 2015, 38, 660-667.	0.7	21
188	PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials. Drug Safety, 2015, 38, 519-526.	1.4	59
189	The Remnants of Residual Riska^—. Journal of the American College of Cardiology, 2015, 65, 2276-2278.	1.2	19
190	Cognitive and Physical Function by Statin Exposure in Elderly Individuals Following Acute Myocardial Infarction. Clinical Cardiology, 2015, 38, 455-461.	0.7	6
191	Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors inÂAtrial Fibrillation. Journal of the American College of Cardiology, 2015, 66, 2899-2906.	1.2	133
192	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	0.6	5
193	Leptin and incident cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2015, 239, 67-72.	0.4	50
194	Statins and Incident Diabetes: Can Risk Outweigh Benefit?. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	2
195	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol. Circulation, 2015, 132, 667-676.	1.6	41
196	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis, 2015, 242, 87-96.	0.4	47
197	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis, 2015, 242, 243-250.	0.4	93
198	Recommendations for the Management of Patients with Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2015, 17, 473.	2.0	13

#	Article	IF	CITATIONS
199	Tools for Cardiovascular Risk Assessment in Clinical Practice. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	0
200	MY APPROACH to patients intolerant to statins*. Trends in Cardiovascular Medicine, 2015, 25, 265-266.	2.3	0
201	Clinician-Patient Risk Discussion forÂAtherosclerotic Cardiovascular DiseaseÂPrevention. Journal of the American College of Cardiology, 2015, 65, 1361-1368.	1.2	142
202	Mobile Health Initiatives to Improve Outcomes in Primary Prevention of Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 59.	0.4	37
203	Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines. Mayo Clinic Proceedings, 2015, 90, 1262-1271.	1.4	16
204	Bringing Back Targets to "IMPROVE―Atherosclerotic Cardiovascular Disease Outcomes. Circulation, 2015, 132, 1218-1220.	1.6	6
205	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). Journal of Clinical Lipidology, 2015, 9, 676-683.	0.6	14
206	Relation of Physical Activity to Prevalence of Nonalcoholic Fatty Liver Disease Independent of Cardiometabolic Risk. American Journal of Cardiology, 2015, 115, 34-39.	0.7	25
207	Impact on Cognitive Function—Are All Statins the Same?. Current Atherosclerosis Reports, 2015, 17, 466.	2.0	7
208	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	1.0	142
209	Cost-Effectiveness of Coronary Artery Calcium Testing for Coronary Heart and Cardiovascular Disease Risk Prediction to Guide Statin Allocation: The Multi-Ethnic Study of Atherosclerosis (MESA). PLoS ONE, 2015, 10, e0116377.	1.1	80
210	Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. Vascular Health and Risk Management, 2014, 10, 205.	1.0	21
211	Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Midâ€Life: The Very Large Database of Lipids (VLDLâ€10B). Journal of the American Heart Association, 2014, 3, e000851.	1.6	54
212	Letter by Jones et al Regarding Article, "Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation― Circulation, 2014, 129, e655.	1.6	13
213	Nonfatal Outcomes in the Primary Prevention of Atherosclerotic Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 481-485.	0.9	3
214	High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle. Atherosclerosis, 2014, 237, 838-839.	0.4	0
215	Are We Moving Towards Concordance on the Principle That Lipid Discordance Matters?. Circulation, 2014, 129, 539-541.	1.6	19
216	Neck Circumference Is Not Associated With Subclinical Atherosclerosis in Retired National Football League Players. Clinical Cardiology, 2014, 37, 402-407.	0.7	20

#	Article	IF	CITATIONS
217	Relation Between Playing Position and Coronary Artery Calcium Scores in Retired National Football League Players. American Journal of Cardiology, 2014, 114, 1836-1840.	0.7	11
218	Improving lipid control following myocardial infarction. Current Opinion in Cardiology, 2014, 29, 454-466.	0.8	7
219	Headed in the Right Direction But at Risk for Miscalculation. Journal of the American College of Cardiology, 2014, 63, 2789-2794.	1.2	69
220	2013 ACC/AHA Cholesterol Treatment Guideline. Journal of the American College of Cardiology, 2014, 63, 2674-2678.	1.2	52
221	Dyslipidemia, Coronary Artery Calcium, and Incident Atherosclerotic Cardiovascular Disease. Circulation, 2014, 129, 77-86.	1.6	212
222	Statins, mood, sleep, and physical function: a systematic review. European Journal of Clinical Pharmacology, 2014, 70, 1413-1422.	0.8	12
223	The new "intermediate risk―group: A comparative analysis of the new 2013 ACC/AHA risk assessment guidelines versus prior guidelines in men. Atherosclerosis, 2014, 237, 1-4.	0.4	19
224	Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis, 2014, 236, 251-256.	0.4	8
225	Non-cardiovascular effects associated with statins. BMJ, The, 2014, 349, g3743-g3743.	3.0	137
226	Discordance in Lipid Measurements: Can we Capitalize to Better Personalize Cardiovascular Risk Assessment and Treatment?. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	1
227	High-density lipoprotein subfractions: current views and clinical practice applications. Trends in Endocrinology and Metabolism, 2014, 25, 329-336.	3.1	42
228	Genetically Low Triglycerides and Mortality: Further Support for "the Earlier the Better�. Clinical Chemistry, 2014, 60, 705-707.	1.5	3
229	Atrial Septal Defects – Clinical Manifestations, Echo Assessment, and Intervention. Clinical Medicine Insights: Cardiology, 2014, 8s1, CMC.S15715.	0.6	46
230	Concepts and Controversies: The 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines. Annals of Internal Medicine, 2014, 160, 356-358.	2.0	41
231	High-Sensitivity C-Reactive Protein and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 397-408.	1.2	399
232	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA - Journal of the American Medical Association, 2013, 310, 2061.	3.8	568
233	How Do Statins Work?. Journal of the American College of Cardiology, 2013, 62, 2392-2394.	1.2	41
234	Non–High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. Journal of the American College of Cardiology, 2013, 62, 1960-1965.	1.2	59

#	Article	IF	CITATIONS
235	Discordance: Can we capitalize on it to better personalize atherosclerosis treatment?. Atherosclerosis, 2013, 229, 504-506.	0.4	7
236	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. Journal of the American College of Cardiology, 2013, 62, 732-739.	1.2	331
237	Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects. Mayo Clinic Proceedings, 2013, 88, 1213-1221.	1.4	181
238	Patient- and Trial-Specific Barriers to Participation in Cardiovascular Randomized Clinical Trials. Journal of the American College of Cardiology, 2013, 61, 762-769.	1.2	68
239	Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. American Heart Journal, 2013, 165, 26-33.e3.	1.2	25
240	Comparing the New European Cardiovascular Disease Prevention Guideline With Prior American Heart Association Guidelines: An Editorial Review. Clinical Cardiology, 2013, 36, E1-6.	0.7	23
241	Very Large Database of Lipids: Rationale and Design. Clinical Cardiology, 2013, 36, 641-648.	0.7	39
242	A Clinician's Guide to the <scp>ABCs</scp> of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clinical Cardiology, 2013, 36, 383-393.	0.7	45
243	Landmark Lipid‣owering Trials in the Primary Prevention of Cardiovascular Disease. Clinical Cardiology, 2013, 36, 516-523.	0.7	19
244	Abstract 442: Correlates of the Triglyceride/HDL Cholesterol Ratio: The Very Large Database of Lipids (VLDL-4). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
245	Abstract 362: Characterization of Triglyceride-Rich Remnant Lipoproteins in the Hypertriglyceridemic Fredrickson-Levy Dyslipidemic Phenotypes without Chylomicrons: The Very Large Database of Lipids (VLDL-6). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
246	Abstract 361: Characterization of Lipoproteins in the Hypertriglyceridemic Fredrickson-Levy Dyslipidemic Phenotypes with Chylomicrons: The Very Large Database of Lipids (VLDL-7). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
247	Lipid Parameters and Cardiovascular Events in Patients Taking Statins. JAMA - Journal of the American Medical Association, 2012, 308, 131.	3.8	1
248	Câ€Reactive Protein Modifies the Association of Plasma Leptin With Coronary Calcium in Asymptomatic Overweight Individuals. Obesity, 2012, 20, 856-861.	1.5	17
249	LDL Cholesterol: The Lower the Better. Medical Clinics of North America, 2012, 96, 13-26.	1.1	73
250	Biatrial thrombus across a patent foramen ovale with fatal pulmonary and coronary embolism. Journal of Echocardiography, 2012, 10, 77-78.	0.4	3
251	Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the Meantime, Some Challenges and Recommendations. American Journal of Cardiology, 2012, 110, 307-313.	0.7	39
252	Comparison of High-Density Lipoprotein Cholesterol to Apolipoprotein A-I and A-II to Predict Coronary Calcium and the Effect of Insulin Resistance. American Journal of Cardiology, 2011, 107, 393-398.	0.7	16

#	Article	IF	CITATIONS
253	Reversible Cardiac Dysfunction Associated With Pandemic 2009 Influenza A(H1N1). Chest, 2010, 137, 1195-1197.	0.4	50
254	Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites. Diabetes, 2009, 58, 1887-1892.	0.3	52
255	Leptin Resistance. Journal of the American College of Cardiology, 2008, 52, 1201-1210.	1.2	434